期刊
JOURNAL OF IMMUNOLOGY
卷 188, 期 3, 页码 1091-1097出版社
AMER ASSOC IMMUNOLOGISTS
DOI: 10.4049/jimmunol.1102045
关键词
-
类别
资金
- Deutsche Forschungsgemeinschaft [BE 3685/1-1, Sonderforschungsbereich Transregio 52 Teilprojekt A1, Teilprojekt A3]
- SCHM [1014/5-1]
- GRK [1043]
- International Graduate School of Immunotherapy
- University Medical Center Mainz
The main molecular mechanism of human regulatory T cell (Treg)-mediated suppression has not been elucidated. We show in this study that cAMP represents a key regulator of human Treg function. Repression of cAMP production by inhibition of adenylate cyclase activity or augmentation of cAMP degradation through ectopic expression of a cAMP-degrading phosphodiesterase greatly reduces the suppressive activity of human Treg in vitro and in a humanized mouse model in vivo. Notably, cAMP repression additionally abrogates the anergic state of human Treg, accompanied by nuclear translocation of NFATc1 and induction of its short isoform NFATc1/alpha A. Treg expanded under cAMP repression, however, do not convert into effector T cells and regain their anergic state and suppressive activity upon proliferation. Together, these findings reveal the cAMP pathway as an attractive target for clinical intervention with Treg function. The Journal of Immunology, 2012, 188: 1091-1097.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据